Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Korro Bio, Inc. KRRO NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
50/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$20.29
+48.3%

Korro Bio, Inc. (KRRO) is a Biotechnology company in the Healthcare sector, currently trading at $13.68. It has a SharesGrow Score of 50/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is KRRO = $20 (+48.3% upside).

Valuation: KRRO trades at a trailing Price-to-Earnings (P/E) of -1.1 (S&P 500 average ~25).

Financials: revenue is $6M, +181.5%/yr average growth. Net income is $117M (loss), growing at -27.7%/yr. Net profit margin is -1834.5% (negative). Gross margin is 33% (-67 pp trend).

Balance sheet: total debt is $43M against $51M equity (Debt-to-Equity (D/E) ratio 0.85, moderate). Current ratio is 6.9 (strong liquidity). Debt-to-assets is 38.3%. Total assets: $114M.

Analyst outlook: 10 / 12 analysts rate KRRO as buy (83%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 94/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 75/100 (Pass), Moat 21/100 (Fail), Future 94/100 (Pass), Income 10/100 (Fail).

$20.29
▲ 48.32% Upside
Average Price Target
Based on 12 Wall Street analysts offering 12-month price targets for Korro Bio, Inc., the average price target is $20.29, with a high forecast of $30.00, and a low forecast of $10.00.
Highest Price Target
$30.00
Average Price Target
$20.29
Lowest Price Target
$10.00

KRRO SharesGrow Score Overview

59/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 94/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 75/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 21/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — KRRO

✓
VALUE Pass
94/100
KRRO trades at a trailing Price-to-Earnings (P/E) of -1.1 (S&P 500 average ~25). Forward PEG -9.7 — Peter Lynch undervalued (≤1.0). Trailing PEG 0.03. Analyst consensus target is $20, implying +46.2% from the current price $14. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
KRRO: +181.5%/yr revenue is, -27.7%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
75/100
Balance sheet KRRO: Debt-to-Equity (D/E) ratio 0.85 (moderate), Current ratio is 6.9 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
21/100
KRRO: Gross margin is 33% (-67 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 21/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
94/100
Analyst outlook: 10 / 12 analysts rate KRRO as buy (83%). Analyst consensus target is $20 (+46.2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
KRRO: Net profit margin is -1834.5%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range5.204-55.89
Volume77.01K
Avg Volume (30D)249.98K
Market Cap$128.59M
Beta (1Y)2.43
Share Statistics
EPS (TTM)-12.48
Shares Outstanding$9.4M
IPO Date2019-10-03
Employees112
CEORam Aiyar
Financial Highlights & Ratios
Revenue (TTM)$6.39M
Gross Profit$2.11M
EBITDA$-83.06M
Net Income$-117.26M
Operating Income$-87.34M
Total Cash$75.16M
Total Debt$43.49M
Net Debt$21.66M
Total Assets$113.51M
Price / Earnings (P/E)-1.1
Price / Sales (P/S)20.12
Analyst Forecast
1Y Price Target$22.00
Target High$30.00
Target Low$10.00
Upside+60.8%
Rating ConsensusBuy
Analysts Covering12
Buy 83% Hold 17% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS5009461089

Price Chart

Track all markets on TradingView
KRRO
Korro Bio, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
5.20 52WK RANGE 55.89

People Also View

LBRX
LBRX
LB Pharmaceuticals Inc Common Stock
$29.12
+9.60%
 ANRO
ANRO
Alto Neuroscience, Inc.
$25.47
-1.36%
 ANNX
ANNX
Annexon, Inc.
$6.35
+9.48%
 DBVT
DBVT
DBV Technologies S.A.
$21.25
-1.80%
 AURA
AURA
Aura Biosciences, Inc.
$7.09
+0.07%
 LRMR
LRMR
Larimar Therapeutics, Inc.
$4.83
-0.82%
 ENGN
ENGN
enGene Holdings Inc.
$7.76
+2.11%
 SLN
SLN
Silence Therapeutics plc
$7.28
+18.95%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message